Aspen expects HEPS down between -40% and -45% to between 814c and 746c for FY25. NHEPS, its preferred measure, is expected down between -27% and -32% to between 1,089c and 1,015c. Results were hit by R4.1bn in impairments, restructuring costs in China, and a dispute in the mRNA manufacturing business that cut manufacturing EBITDA by around 60%. Commercial Pharmaceuticals delivered double-digit revenue growth in constant currency, supported by Mounjaro in SA and acquisitions in Latam, while strong cash conversion is expected to hold leverage between 3.15x and 3.2x.
Click here to read the SENS